AstraZeneca Teams With Vanderbilt In Neuroscience Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
Vanderbilt University’s neuroscience research group reaches its latest agreement with a pharma, this one covering compounds that treat symptoms of Alzheimer’s disease and schizophrenia by modulating a receptor in new ways.
You may also be interested in...
Academic Drug-Discovery Units Team Up To Share Knowledge, Facilitate Partnering
Founded in 2012, the Academic Drug Discovery Consortium intends to serve as a clearinghouse for both academia and industry on research underway at U.S. and international drug research programs. It won’t undertake tech transfer work itself, but the ADDC hopes to make it easier for academics and biopharma to work together.
Pursuit Of R&D Efficiency Continues As Regulatory Options Expand In 2013 – Tufts CSDD
Cutting non-core procedures – such as those supporting exploratory endpoints – from study budgets could save the industry $6 billion a year in drug development costs, the Tufts Center for the Study of Drug Development suggests in its 2013 industry outlook report.
Deals Of The Week: AstraZeneca/Vanderbilt, Medicago, OcellO/Merus
High-level executive changes at AstraZeneca continue pondering of where the British pharma turns next for growth – will it look to large-scale M&A again?